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ImmunityVaccines play a vital role in protecting the host against infectious disease. The most effective licensed vaccines
elicit long-term antigen-speciﬁc antibody responses by plasma cells in addition to the development of
persisting T cell and B cell memory. The relative contributions of these different immune cell subsets are
context-dependent and vary depending on the attributes of the vaccine (i.e., live/attenuated, inactivated, and
subunit) as well as the biology of the pathogen in question. For relatively simple vaccines against bacterial
antigens (e.g., tetanus toxin) or invariant viruses, the immunological correlates of protection are well-
characterized. For more complex vaccines against viruses, especially those that mutate or cause latent
infections, it is more difﬁcult to deﬁne the speciﬁc correlates of immunity. This often requires observational/
natural history studies, clinical trials, or experimental evaluation in relevant animal models in order for
immunological correlates to be determined or extrapolated. In this review, we will discuss the relative
contributions of virus-speciﬁc T cell and B cell responses to vaccine-mediated protection against disease.na), slifkam@ohsu.edu
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Vaccines play a fundamental role in modern medicine and the
introduction of Edward Jenner's smallpox vaccine in 1798 marked an
important turning point in the battle against infectious disease
(Jenner, 1798). With the notable exceptions of smallpox and rabies,
many of the early advances made in vaccinology during the 18th and
19th centuries were focused primarily on bacterial pathogens (Plotkin
and Plotkin, 2008). These initial studies reﬂect the tools that weredeveloped by early microbiologists to grow and study important
pathogenic bacteria as well as some of the challenges faced by
virologists prior to the advent of modern tissue culture technologies.
During the 20th century, new viral vaccines against yellow fever,
inﬂuenza, polio, measles, mumps, rubella, and others emerged. Today,
there are now 14 vaccines licensed in the US that are directed against
viral pathogens (Table 1) (FDA, 2010).
Development of an effective vaccine is only the ﬁrst step in
controlling or eradicating a particular disease. For instance, despite
the development of an effective measles vaccine in the 1960s, this
virus is still a signiﬁcant health threat worldwide, with an estimated
10% of deaths in children less than 5 years of age attributed to
complications from measles (CDC, 1998). In the pre-vaccine era,
Table 1
Correlates and surrogates of vaccine-mediated immunity to viruses.a
Vaccine Vaccine type Test Protective level Reference
Hepatitis A Inactivated ELISA 10 mIU/mL Fiore et al. (2008) and Nalin et al. (1993)
Hepatitis B (HbsAg) Protein ELISA 10 mIU/mL Jack et al. (1999)
Human papillomavirus Virus-like particles ELISA NDb Schiller et al. (2008)
Inﬂuenza Inactivated/live attenuated HAI 1:40 titer Dowdle et al. (1973)
Japanese encephalitis virus Inactivated/live attenuated Neutralization 1:10 titer Hombach et al. (2005)
Measles Live attenuated Neutralization 120–200 mIU/mL Chen et al. (1990) and Samb et al. (1995)
Mumps Live attenuated Neutralization? ND Weibel et al. (1975)
Polio Live attenuated/inactivated Neutralization 1:4 to 1:8 titer Plotkin and Vidor (2008)
Rabies Inactivated Neutralization 0.5 IU/mL WHO (2007)
Rotavirus Live attenuated Serum IgA ND Franco et al. (2006)
Rubella Live attenuated ELISA, Immunoprecipitation 10–15 mIU/mL Matter et al. (1997) and Skendzel (1996)
Smallpox Live attenuated Neutralization 1:20 to 1:32 titer Mack et al. (1972) and Sarkar et al. (1975)
Varicella Live attenuated FAMA, gpELISA 1:64 titer, 5 IU/mL Li et al. (2002) and White et al. (1992)
Varicella zoster Live attenuated T cell proliferation ND Weinberg et al. (2009)
Tick-borne encephalitis virus Inactivated Neutralization ND Kreil et al. (1997)
Yellow fever Live attenuated Neutralization 0.7 LNI Mason et al. (1973)
a Adapted from Plotkin (2008, 2010) with modiﬁcations. The correlates and surrogates of immunity for most vaccines are based on serum antibody titers, but several vaccines also
induce mucosal immunity and/or T cell-mediated immune responses.
b ND, not deﬁned.
Fig. 1. Contribution of efﬁcacy, safety, feasibility, and cost to the development of
vaccines. The development of a new vaccine is not based on protective efﬁcacy alone. In
order for a vaccine to be highly successful, it will need to meet minimum standards for
efﬁcacy, safety, feasibility, and cost. These are each important and inter-related
considerations in the vaccine development process and only through the combined
efforts of the manufacturer, regulatory authorities, and public health administrators,
will a vaccine against a particular pathogen be fully utilized (Plotkin, 2005).
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year (Amanna and Slifka, 2005). Following the introduction of
measles vaccination, the number of cases has dropped dramatically
(Amanna and Slifka, 2005) — with only 127 cases reported in 2008
(Hall-Baker et al., 2010). Importantly, of those reporting measles, 78%
(99/127) were unvaccinated, often for personal or religious beliefs.
Most of these cases of measles were concentrated among groups of
unvaccinated individuals who rapidly spread the disease through
their local community (Hall-Baker et al., 2010). Fortunately, despite
these small outbreaks, measles is still well controlled at a population
level. In the past, introduction of a viral pathogen could decimate a
naive population, often with a disproportionate effect on vulnerable
populations including the very young and very old (Siegrist, 2008).
This does not occur in the context of high vaccination coverage (e.g.,
measles vaccination in the U.S.) due in large part to herd immunity.
When vaccination coverage is high, the transmission of contagious
disease is reduced and this protects vulnerable individuals from
encountering the pathogen and becoming infected. The goal of herd
immunity is to attain immunization levels that stop the endemic
spread of transmissible diseases, which may require immunization
rates of N90% for some of themost contagious viruses, such as measles
(Fine and Mulholland, 2008). Herd immunity is critical from a public
health perspective because often the most vulnerable populations in a
community (e.g., infants, elderly, and immunocompromised) are also
the least likely to respond effectively to vaccination. This is an
increasingly important topic, considering that the proportion of
elderly individuals in the world is expected to rise from 10% in 2000
to 21% in 2050 (Aspinall et al., 2007).
Continued innovation in vaccine research has resulted in a
relatively large number of antiviral vaccines that have been licensed,
as well as a number more that are in various stages of development
(Table 1). Production of a successful vaccine is not a trivial process and
requires a strong foundation based on safety, feasibility, cost, and
above all, proof of protective efﬁcacy (Fig. 1). These basic tenets have
factored into the research and development of essentially all licensed
vaccines, including the very ﬁrst vaccine developed by Edward Jenner
(1798). After describing substantial epidemiological evidence show-
ing that natural cowpox infection (or perhaps, horsepox; Dasgupta et
al., 2007; Tizard, 1999; Tulman et al., 2006) could protect against
smallpox, Jenner began his studies by performing variolation
(inoculation of smallpox, i.e., Variola virus, into the skin). This
approachwas used successfully to determine if prior cowpox infection
could indeed protect against Variola. As early as 1795, Jenner noted,
“…though the variolousmatter was repeatedly inserted into his arm, I
found it impracticable to infect him with it; an efﬂorescence only,taking on an erysipelatous look about the centre, appearing on the
skin near the punctured parts. During the whole time that his family
had the smallpox, one of whom had it very full, he remained in the
house with them, but received no injury from exposure to the
contagion” (Jenner, 1798). This provided important proof-of-princi-
ple, but to demonstrate actual vaccine-mediated protection, Jenner
experimentally infected subjects with cowpox by scariﬁcation and
then performed variolation. Similar to natural cowpox infection,
direct vaccination with cowpox provided protection against Variola
virus. This not only demonstrated protective efﬁcacy, but because
cowpoxwas farmore attenuated and safer to use than variolation (the
standard of care at that time), Jenner had greatly increased the safety
of his approach. In terms of technical feasibility (as well as safety),
Jenner was very careful to train other physicians in the art of
scariﬁcation and to inform them of the nature of his vaccine approach,
which utilized appropriate pustulate and not “putriﬁed” material.
Indeed, by the time Jenner had published his 3rd study on smallpox
vaccination, upwards of 6000 subjects had been vaccinated, many of
whom were also tested for protective immunity. According to Jenner,
“… the far greater part of them have since been inoculatedwith that of
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be devised, without effect” (Jenner, 1800). This body of work is similar
to a modern Phase III clinical trial in both size and scope and
undoubtedly played a role in the eventual use of this radical new
approach to preventative medicine. In addition to protective efﬁcacy,
it was also important that Jenner demonstrated that arm-to-arm
transmission between humans was possible, so that vaccine produc-
tion was not reliant on sporadic outbreaks in cows (Plotkin and
Plotkin, 2008). Although this provided initial feasibility at small scale,
for the global eradication effort, further technical and safety
reﬁnements were made, including the development of vaccine
production based on glycerinated calves' lymph (Plotkin and Plotkin,
2008). By scarifying calves and harvesting/lyophilizing the virus-
infected lymph for vaccine use, both safety and feasibilitywere greatly
improved. In addition, because millions of doses of vaccine could be
mass-produced at low cost, this further increased the feasibility of
global use of the smallpox vaccine. In the end, this resulted in the ﬁnal
eradication of smallpox by 1980 (Fenner et al., 1988).
The current timeline for taking a vaccine from concept to licensed
product is estimated at 10–15 years, though some licensed vaccines
have taken up to 30 years (Douglas et al., 2008). This extended
timeline is due largely to the stringent pre-clinical and clinical testing
that is required of human vaccine candidates. Vaccine development
can also be expensive — with estimates approaching $500 to $800
million to bring a vaccine to market (Douglas et al., 2008). Over time,
advanced manufacturing techniques have reduced the costs of
production but improvements in vaccine safety have resulted in
increased costs as well. Vaccine safety is of growing importance
because public fear of vaccination can dramatically reduce vaccine
uptake and coverage, resulting in reduced herd immunity and in some
cases, re-emergence of outbreaks of vaccine-preventable diseases
such as measles (Amanna and Slifka, 2005; Jansen et al., 2003). To
combat this trend, there is a push for higher vaccine purity, higher
sterility assurance levels, reduction of animal-origin additives,
enhanced testing for adventitious agents, and removal of preserva-
tives — which has come with an associated increase in the usage of
single dose containers (Gomez et al., 2008). Although these steps
improve safety, this does not come without a cost. Indeed, the simple
step of switching from multi-dose vials to single-dose vials can itself
increase manufacturing costs by 250% (Lee et al., 2010). The ability of
vaccine manufacturers to respond to updated regulatory require-
ments as well as unfounded or misguided fears of vaccinesmay have a
signiﬁcant impact on the development, availability, and cost of new
vaccines in the future.
Persisting antibody following vaccination; the ﬁrst line of defense
against infection
In the past, the development of a potent antibody response has
been the hallmark of a good vaccine and is the probable mechanism
underlying vaccine efﬁcacy for many of today's most successful
vaccines (Plotkin, 2010; Siegrist, 2008). Several vaccines have deﬁned
levels of serum antibody (as measured by ELISA, hemagglutination, or
neutralization assays) that serve as correlates or surrogates of
protective immunity (Table 1) (Plotkin, 2010). The smallpox vaccine
was developed prior to the development of immunological tools but
visual inspection of a “take” or Jennerian vesicle at the vaccination site
served as a surrogate of protection. Field studies performed in the
1970s have since indicated that a neutralizing titer of 1:20 (Sarkar et
al., 1975) to 1:32 (Mack et al., 1972) is likely to be sufﬁcient to provide
protective immunity against smallpox. The yellow fever vaccine was
developed in the 1930s (Monath et al., 2008) and, similar to the
smallpox vaccine, there were no immunological assays available at
that time that could be used to determine a correlate of immunity.
However, in 1973 a series of experiments performed in rhesus
macaques given varying doses of the yellow fever vaccine providedevidence that protection against lethal yellow fever challenge
occurred in the majority of animals with neutralizing antibody titers
of ≥0.7 LNI (log neutralizing index) (Mason et al., 1973). For measles,
antiviral antibody levels of 120–200 mIU/mL are considered protec-
tive. A retrospective epidemiological study of a measles outbreak that
occurred in a dormitory setting shortly following a blood drive
provided the opportunity to determine the levels of pre-existing anti-
measles antibody that were needed to protect students from overt
disease (≥200 mIU/mL) (Chen et al., 1990). In an independent study,
antibody levels measured within 10 days of exposure to measles
indicated that children with neutralizing titers above 125 mIU/mL
were protected against clinical measles (Samb et al., 1995). Memory T
cells and memory B cells were not examined in these studies and it is
uncertain what contributions were made by these cell populations.
However, review of vaccine-mediated immunity against smallpox and
yellow fever indicates that pre-existing antibody plays the predom-
inant role in protection (Amanna et al., 2008).
Plasma cell contributions to vaccine-mediated immunity
The mechanisms that underpin that long-term antibody responses
remain controversial (Amanna and Slifka, 2010; Elgueta et al., 2010;
Radbruch et al., 2006). Terminally differentiated plasma cells (PC) are
the primary source of serum antibody and antibody secreting cells
may produce up to 20,000 molecules of immunoglobulin per second
(Conrad and Ingraham, 1974; Helmreich et al., 1961, 1962). With the
ability to block virus at the site of infection or prevent/reduce systemic
spread, pre-existing antibody plays a clear role in vaccine-mediated
defense against infection. At the mucosal surfaces, where many
pathogens gain entry to the host, IgA plays a signiﬁcant protective
role. Mucosal IgA is generated by local PC and released as dimeric IgA
(dIgA). After release from the PC, dIgA can bind the polymeric
immunoglobulin receptor (pIgR) at the basolateral surface of mucosal
epithelial cells. This complex is actively transported through the
epithelial cell, cleaved to form fully mature secretory IgA (SIgA), and
then excreted into the mucosa. Several vaccines, such as those
targeting cholera and typhoid fever, have been developed speciﬁcally
to promote SIgA responses through oral administration, but immunity
appears to wane shortly after vaccination (Holmgren and Czerkinsky,
2005).
By contrast, parenterally administered vaccines often elicit long-
lived serum IgG responses, but limited SIgA responses. IgG is
maintained at approximately 10 mg/mL in the circulation and is
important in combating systemic viral infections. Indeed, passive
immunotherapy has been used for decades to treat agammaglobu-
linemia as well as a number of infectious diseases (Amanna and Slifka,
2009; Casadevall, 1999; Eibl, 2008). In addition, through the process
of transudation, IgG may also play an important role at mucosal sites.
While the active transfer of SIgA across epithelial barriers is well
described, the mechanism for IgG transudation is often described as
passive diffusion, though active transport has been reported (Spie-
kermann et al., 2002). Nevertheless, transudation of high-titer serum
IgG is thought to have a signiﬁcant protective role against several viral
pathogens. For example, vaccines against human papilloma virus
(HPV), an infectious agent of global importance, may protect
primarily through the transudation of serum IgG at the cervical
mucosa (Schwarz and Leo, 2008). In one preliminary study with a
relatively small number of subjects, investigators found that non-
ovulating women had a positive correlation between cervical
antibody titers and serum antibody titers (r=0.86) whereas ovulat-
ing women did not (r=0.27) (Nardelli-Haeﬂiger et al., 2003). In the
genital tract, transudation is believed to occur through a process of
mass transfer, where an imbalance of hydrostatic pressures forces the
serum IgG across the blood capillary walls into the cervical mucus
(Schwarz and Leo, 2008). Similar mechanisms of transudation also
play a role in protecting against respiratory infections. Respiratory
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and children that has eluded the development of a successful vaccine
(Blanco et al., 2010). However, one of the most effective preventative
strategies for at-risk infants is the parenteral administration of a
highly neutralizing IgG monoclonal antibody (Empey et al., 2010;
Krilov et al., 2009). The use of parenterally administered IgG for the
speciﬁc neutralization of a respiratory pathogen again points to the
ability of systemic IgG to play an important role at mucosal surfaces,
especially those in which severe disease is associated with infection of
the lower respiratory tract. Given the importance that systemic
antibody responses have in protection against viral infection, a key
goal for vaccine development is to induce effective, long-term
antibody responses. In order to achieve this goal, it is important to
understand the mechanisms involved with generating persistent
antibody responses and immunological memory.
The theories underlying PC survival (and therefore antibody
maintenance) fall into two general categories (Amanna and Slifka,
2010). One theory is that long-lived antibody responses arememory B
cell (MBC)-dependent and that MBC are required to undergo a certain
degree of proliferation resulting in antibody-producing daughter cells
which home to the BM, replenish declining PC numbers and maintain
steady-state levels of serum antibody (Bernasconi et al., 2002;
Traggiai et al., 2003). An alternative theory is that long-lived antibody
responses are MBC-independent and that plasma cells can be
intrinsically long-lived and able to sustain protective antibody
responses for long periods of timewithout the need for replenishment
(Amanna and Slifka, 2010; Elgueta et al., 2010; Radbruch et al., 2006;
Slifka and Ahmed, 1998). Tritium incorporation studies in rats
indicate that PC (or their immediate precursors) can be long-lived
(Miller, 1964). Likewise, using modern techniques such as BrdU
incorporation, PC have also been shown to be long-lived with little
turn-over (Manz et al., 1997). One caveat is that a MBC could
theoretically differentiate into a PC without undergoing cell division.
This may be unlikely since several studies have shown that antibody
responses are relatively resistant to MBC depletion (Ahuja et al., 2008;
DiLillo et al., 2008; Slifka et al., 1998). Similarly, limited observational
studies in human subjects treated with anti-CD20 antibodies indicate
that vaccine-mediated antibody responses against tetanus remain
largely unaltered for at least one year following depletion of
peripheral CD20+ B cells (Cambridge et al., 2003). Taken together,
these lines of evidence indicate that long-lived PC are the cell type
responsible for maintaining long-term vaccine-induced antibody
responses.
Despite a central role in vaccine-mediated immunity, the molec-
ular mechanisms that drive PC development and allow for prolonged
survival remain largely unknown. A subpopulation of long-lived PC
remains in the spleen and/or draining lymph nodes following
infection or vaccination, but the majority of PC occupy survival niches
within the bone marrow (Benner et al., 1981; Hyland et al., 1994;
Slifka et al., 1995; Tokoyoda et al., 2009). It is assumed that
chemotactic factors allow plasma cells to migrate to the BM, and
once there, local adhesion and/or chemokine factorsmaintain survival
(Tokoyoda et al., 2009). However, given the complexity and possible
redundancy of chemokine signaling, it may be difﬁcult to determine
the key factors involved in this process. For instance, while the
CXCL12–CXCR4 interaction has been shown to be important in the
early migration of PC to the BM (Hargreaves et al., 2001; Hauser et al.,
2002), it seems to be dispensable for long-term antibody responses
(Nie et al., 2004). Similarly, although IL-6may be important for in vitro
survival of isolated PC (Cassese et al., 2003), IL-6-deﬁcient mice
demonstrate no long-term humoral defects following immunization
with the prototypical T cell-dependent antigen, ovalbumin (Cassese et
al., 2003). In contrast, in vivo blockade of the adhesionmolecules, LFA-
1 (lymphocyte-associated antigen-1) and VLA-4 (integrin α4β1, very
late antigen-4) leads to the rapid loss of a previously established
antigen-speciﬁc antibody response (DiLillo et al., 2008). PC survivalsignals provided through the TNF family members, BAFF (B cell-
activating factor of the TNF family) and APRIL (a proliferation-
inducing ligand), have recently gained attention in PC maintenance.
Both BAFF (also known as BlyS) and APRIL can bind the TNF receptors,
TACI (transmembrane activator and calcium modulator ligand
interactor) and BCMA (B cell maturation antigen), with only BAFF
binding to the BAFF receptor (BAFF-R) (Mackay and Schneider, 2009).
This system has been well described in peripheral B cell survival and
development, but until recently, the role of BAFF and APRIL (and their
associated receptors) in plasma cell development remained unclear.
The ﬁrst demonstration that this system might also affect terminal B
cell development came from analysis of BCMA knockout mice
(O'Connor et al., 2004). These animals demonstrated normal
induction of TD antibody responses but showed decreased mainte-
nance of PC. These details, along with the observation that BCMA
surface receptor expression in humans appears limited to CD138+ B
cells (Darce et al., 2007), point to the BAFF/APRIL:BCMA interactions
as a key survival mechanism for PC. Further information to support
this hypothesis was recently demonstrated through blockade of in
vivo signaling by administration of soluble versions of BAFF-R (blocks
only BAFF) and TACI (blocks both BAFF and APRIL) (Benson et al.,
2008). The concurrent blockade of BAFF and APRIL led to a signiﬁcant
drop in antigen-speciﬁc plasma cells, 3 months after the establish-
ment of a TD immune response. Intriguingly, while this blockade
decreased the number of established PC, MBC populations appeared
resistant to treatment, again pointing to a divergence between these
two B cell populations. Based on adoptive transfer studies with
BAFF−/− or APRIL−/− deﬁcient mice, APRIL appears to have a
predominant role over BAFF in supporting long-lived PC development
and maintenance (Belnoue et al., 2008). Blimp-1 (B-lymphocyte
induced maturation protein-1) expression is critical for both the
development and maintenance of plasma cells. (Kallies and Nutt,
2007). Loss of Blimp-1 expression in conditional Blimp-1 knockout
mice results in a signiﬁcant drop in previously established TD
antibody responses (Shapiro-Shelef et al., 2005). Deﬁciencies in the
adaptor protein, SAP (SLAM-associated protein), allow the initial
production of normal antibody titers, but long-term antibody
maintenance is signiﬁcantly impaired (Crotty et al., 2003b), possibly
due to decreased contact time between B cells and T cells in the GC
reaction (Qi et al., 2008). Further investigation into the key
mechanisms that support PC survival in vivo, possibly through
Blimp-1 and SAP expression, could be important in understanding
the nature of long-term vaccine-mediated antibody responses.
The role of memory B cells in vaccine-mediated immunity
Unlike antibody-secreting plasma cells, vaccine-induced memory
B cells do not provide direct protection against infection. Instead, they
represent an important second line of immune defense that is
initiated only if pre-existing antibody levels are too low to prevent
infection or if the invading pathogen is able to circumvent the pre-
existing antibody response (e.g., high dose exposure or antigenic
mutation). Live-attenuated dengue virus vaccination provides an
interesting case in point. To be effective, this vaccine requires
tetravalent antibody responses against all 4 serotypes of dengue
(Whitehead et al., 2007). Following primary vaccination, neutralizing
antibody responses are typically directed to only a subset of the 4
serotypes but booster vaccination fails to elicit antibody responses to
the remaining dengue serotypes unless vaccinations are spaced at
least 4–6 months apart (Morrison et al., 2010;Whitehead et al., 2007).
This indicates that pre-existing immunity in the form of circulating
antibodies (and potentially virus-speciﬁc T cells) prevents infection
by the vaccine strains of virus to the point that primary B cell
responses and anamnestic responses bymemory B cells are blunted or
prevented altogether due to lack of sufﬁcient viral replication. This
pre-existing antibody-based phenomenon is not new; it has long been
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induction of host immunity in infants, and this is especially
problematic for replicating live-attenuated vaccines such as the
MMR vaccine (Hayden, 1979). To overcome primary vaccine failure
due to the protective effect of pre-existing maternally-derived
antibodies, the timing of MMR vaccination is based primarily on
two factors; 1) the earliest age at which high seroconversion rates can
be consistently elicited and 2) the age group with the highest risk of
severe disease (Orenstein et al., 1986; Strebel et al., 2008). Bearing
these factors in mind, pre-existing antibody represents the initial
protective barrier elicited by vaccine-induced immunity and memory
B cell responses are invoked only if a given pathogen has breached this
critical ﬁrst line of defense.
Following vaccination or viral infection, memory B cell responses
can be remarkably long-lived. For example, vaccine-induced B cell
memory is maintained for decades after smallpox vaccination (Crotty
et al., 2003a). This is not unique to this one vaccine since a number of
other virus and vaccine antigens also induce long-lived memory B cell
responses (Amanna et al., 2007). Memory B cells maintain cell surface
expression of membrane-bound immunoglobulins (which together
with Igα and Igβ form the B cell receptor; BcR), and B cells typically
require crosslinking of the BcR in order to become fully activated to
proliferate and differentiate into antibody-secreting daughter cells
(Metzger, 1992; Pierce and Liu, 2010). In vitro, this can be
accomplished by exposing B cells to staphylococcal protein G
(which binds IgG molecules) in combination with toll-like receptor
activation (Crotty et al., 2004). In addition, memory B cells can also be
activated in vitro by combinations of TLR agonists and cytokines in the
absence of BcR stimulation (Bernasconi et al., 2002), but in vivo,
activation through the BcR is most likely to be triggered by re-
infection and subsequent direct exposure to speciﬁc cognate antigen
(Amanna and Slifka, 2010). The lack of continuous polyclonal
activation and differentiation into antibody-secreting plasma cells
may explain why B cell memory persists following hepatitis B
vaccination despite the loss of detectable anti-HBsAg antibodies in
the serum. Moreover, this may also explain why B cell memory is
insufﬁcient to protect against acute hepatitis B infection (as indicated
by induction of hepatitis B core-speciﬁc antibodies), but appears to
protect against progression to chronic hepatitis (Lin et al., 2003;
Whittle et al., 1995; Young et al., 2003). Similarly, B cell memory is
observed following vaccination with Haemophilus inﬂuenzae b (Hib)
even after serum antibody responses have dropped below detection
(Goldblatt et al., 1998) but pre-existing B cell memory may not
necessarily prevent invasive Hib-associated disease (Lambert et al.,
2005; McVernon et al., 2003). This suggests that the role of memory B
cells is not to block infection per se or to maintain serum antibody
levels (Amanna and Slifka, 2010), but instead represents an
independently regulated B cell population (Amanna et al., 2007;
Nanan et al., 2001) that is involved with eliciting anamnestic antibody
responses and, in certain cases, reducing disease severity following
infection. It is important to note that this role for memory B cells may
be applicable only to pathogens that have a relatively long incubation
period prior to disease progression, which allows for B cell activation,
proliferation, differentiation, and de novo synthesis of antibody to
occur in order to ameliorate ensuing pathology.
The contribution of memory T cells to vaccine-mediated
protection
Virus-speciﬁc CD8+ T cells and CD4+ T cells represent the cellular
arm of adaptive immunity triggered during infection or vaccination.
Similar to memory B cells, memory T cells do not directly block
infection, but they can reduce or eliminate viral replication after
infection has occurred. For viruses that cause disease mainly through
systemic spread (e.g., polio) or lower respiratory tract infection (e.g.,
inﬂuenza), protective immunity is typically attributed to pre-existingantigen-speciﬁc antibodies and pre-existing T cell memory may not
be required to spare the individual from death or severe disease. This
does not mean that T cells are unimportant — indeed, by reducing
viral replication, vaccine-induced antibodies may function, at least in
part, by suppressing viral growth until primary T cell responses are
mounted. Not surprisingly, many of the ﬁrst successful vaccines were
developed against viruses that reside within this category of
pathogens. However, for more complex viruses with a large number
of serotypes (e.g., adenoviruses), rapid mutation rates (e.g., HIV) or
the ability to form latency (e.g., EBV, CMV, HSV, VZV, and HIV), the
role of strong cellular immune responses in controlling and containing
infection becomes increasingly important.
Memory T cells possess several key functional attributes that
distinguish them from their naïve counterparts. Memory T cells can
respond to lower amounts of peptide antigen, produce a wider array
of inﬂammatory or antiviral cytokines, elicit rapid cytolytic activity,
and home efﬁciently to either lymphoid or non-lymphoid compart-
ments (Kaech et al., 2002; Lefrancois, 2006; Sallusto et al., 2010;
Whitton et al., 2004). It was thought that memory T cells also
proliferated more rapidly than naïve T cells following viral infection,
but accumulating evidence (Stock et al., 2006; Whitmire et al., 2008)
indicates that both CD4+ and CD8+ memory T cells undergo a 48–
72 hour lag period that is similar to naïve T cells prior to initiating an
antigen-speciﬁc proliferation program. Following this initial lag
period, T cell proliferation in vivo is extremely rapid, reaching
estimated cell division rates of once every 6–8 h (Murali-Krishna et
al., 1998), 4 h (Lawrence and Braciale, 2004; Whitmire et al., 2008) or
possibly as short as once every 2 h (Yoon et al., 2010). There is much
to be learned about the biological mechanisms that allow for such
rapid cell division to occur in vivo. Antigen-speciﬁc T cells are known
to “cannibalize” target cells by incorporating APCmembranes into the
responding T cell by a process of TcR-mediated endocytosis (Arnold et
al., 1997; Beadling and Slifka, 2006; Huang et al., 1999; Hudrisier and
Bongrand, 2002; Hudrisier et al., 2001; Hwang et al., 2000; Joly and
Hudrisier, 2003; Nepom et al., 1981; Patel et al., 1999; Rosenits et al.,
2010; Tomaru et al., 2003; Tsang et al., 2003; Wetzel et al., 2005). It
would be interesting if the active acquisition of APC membranes
during peptide-speciﬁc cell-to-cell interactions turns out to be an
underlying mechanism that allows T cells to conserve metabolic
energy while at the same time proliferating with extremely rapid
doubling times during the critical early stages of infection.
Virus-speciﬁc T cell subsets were once broadly deﬁned as
activated “effector” T cells identiﬁed at or near the peak of an
antiviral T cell response or they were deﬁned as resting “memory”
T cells following resolution of viral infection/viral clearance. Memory
T cell populations have been further divided into “central memory”
(TCM; CCR7+/CD62L+CD28+CD95+) or “effector memory” (TEM;
CCR7−/CD62L−CD28−CD95+) subsets that differ by phenotype and
function (Sallusto et al., 2004, 1999). When initially deﬁned, TCM were
believed to reside in lymphoid tissues and lack immediate effector
function, but were able to proliferate and different into TEM following
challenge. In contrast, TEM reside primarily in non-lymphoid tissues
and demonstrate more rapid effector functions (Sallusto et al., 1999).
At least a subpopulation of TEM continues to be found in lymphoid
tissues after resolution of viral infection, but interestingly, CD62L− TEM
and CD62L+ TCM preferentially home to different anatomical sites
within the spleen (Jung et al., 2010). Further studies have indicated
that both TCM and TEM rapidly express effector functions including
cytokine production and cytolytic activity (Wherry et al., 2003) and it
is thought that their anatomical location is perhaps more important
than the speed at which they become effectors (Sallusto et al., 2010).
In terms of vaccine-mediated protection, it is unclear if TCM or TEM
are the most important subset for eliciting protection against viral
challenge. In mice, virus-speciﬁc TCM are more protective than TEM
when faced with respiratory (i.e., mucosal) vaccinia virus infection,
acute systemic vaccinia virus infection, or chronic systemic LCMV
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rhesus macaques with recombinant RhCMV vectors that induce
primarily TEM T cell responses has been shown to provide substantial
protection against mucosal SIV challenge (Hansen et al., 2009). One
complication with these narrowly deﬁned TCM or TEM subsets is that
they are not homogeneous memory T cell populations. Each of these T
cell populations can be further divided into more discrete T cell
subsets with deﬁned antiviral functions, phenotypic markers, and
tissue homing capacity (Sallusto et al., 2004). Indeed, there is
evidence that other activation markers such as CD27 and CD43 may
be superior to the TCM/TEM differentiation marker, CD62L, in
predicting the recall responses of memory T cells upon viral challenge
(Hikono et al., 2007). Likewise, the surface antigens, KLRG1 and
CD127, have been used extensively to subdivide effector and memory
T cell subsets and these phenotypic markers are useful for predicting
whether the virus (or vaccine) induces primarily short-lived memory
(KLRG1+ CD127−) or long-lived memory (KLRG1−CD127+) T cell
responses (Cui and Kaech, 2010; Huster et al., 2004; Joshi et al., 2007;
Kaech et al., 2003; Schluns et al., 2000). It is possible that different
types of T cell memory will be required for different viral pathogens
and this will most likely need to be determined on a case-by-case
basis.
Cytotoxic CD4+ T cells — are they involved with protection
following human vaccination?
There has been considerable emphasis placed on the induction and
analysis of vaccine-induced CD8+ T cell responses. CD4+ T cell
responses, on the other hand, are thought to be more important for
development of effective humoral immune responses (i.e., T cell-
dependent antibody responses) and the induction of effective CD8+ T
cell responses. However, the potential protective role for vaccine-
induced CD4+ T cells during infection is not as well characterized.
Cytotoxic MHC Class II-restricted CD4+ T cell responses have been
identiﬁed in mice (Brown et al., 2009; Jellison et al., 2005) but in
rodents, CD8+ CTL responses appear to be much more common. In
contrast, there are several examples of virus-speciﬁc MHC Class II-
restricted CD4+ CTL responses that have been described in clinical
studies (Bourgault et al., 1989; Demkowicz et al., 1996; Erickson and
Walker, 1993; Littaua et al., 1992; Martorelli et al., 2010; Mitra-
Kaushik et al., 2007; Penna et al., 1992; Schmid, 1988; Walker and
Slifka, 2010) as well as in chimpanzees (Zarling et al., 1987). Cytotoxic
CD4+ T cells have been identiﬁed directly ex vivo following human
measles virus infection (Jaye et al., 1998). Moreover, virus-speciﬁc
CD4+ T cell memory can also be long-lived and following in vitro
restimulation, cytotoxic CD4+ T cells have been identiﬁed for up to
50 years after smallpox vaccination (Demkowicz et al., 1996).
Induction of cytolytic CD4+ T cell responses have been documented
following infection with a number of viruses including measles (Jaye
et al., 1998), vaccinia virus (Demkowicz et al., 1996; Erickson and
Walker, 1993; Littaua et al., 1992; Mitra-Kaushik et al., 2007), polio
(Wahid et al., 2005), dengue (Green et al., 1997), inﬂuenza (Bourgault
et al., 1989), hepatitis B virus (Penna et al., 1992), varicella zoster
virus (Arvin et al., 1991), Epstein Barr virus (Bourgault et al., 1989;
Martorelli et al., 2010; Munz et al., 2000), herpes simplex virus
(Schmid, 1988) and CMV (Appay et al., 2002; Gyulai et al., 2000) as
well as after vaccinationwith non-replicating antigens such as tetanus
toxoid (Valmori et al., 1994). One caveat to the potential effectiveness
of cytotoxic CD4+ T cell memory is that they would be limited to
recognition of only a subset of host cells that express MHC Class II.
However, this may not be an overriding limitation because many cell
types including T cells (Miller et al., 2008) and respiratory epithelial
cells (Hegde and Johnson, 2003; Papon et al., 2002; Rees et al., 2003;
Rossi et al., 1990; Striz et al., 2000; Wang et al., 1997) have the ability
to upregulate MHC Class II (e.g., HLA-DR) expression following
activation. Bearing this in mind, it is possible that cytotoxic CD4+ Tcells in humans and non-human primatesmay play amore substantial
role in mucosal immunity than previously believed and this
represents an important area that is worthy of further investigation.
Challenges in deﬁning vaccine-mediated correlates of immunity
to complex pathogens
Nearly all FDA-approved vaccines use seroconversion as the
primary endpoint for determining vaccine immunogenicity. The
only exception to this rule is the vaccinia virus-based smallpox
vaccines, Dryvax and ACAM2000, in which the primary endpoint is
development of a pustular lesion (i.e., a Jennerian vesicle) at the site of
vaccination (Amanna et al., 2008). It is important to note that the use
of serum antibody titers as the primary endpoint does not necessarily
mean that the protective immunity elicited by a particular vaccine is
mediated by antibodies. In the past, serological analysis of vaccine
immunogenicity was easier to perform, more amenable to high
throughput analysis, and often easier to interpret than the analysis of
vaccine-mediated T cell responses. This is especially true for vaccines
that were developed and approved before the 1970s when reagents
for analyzing T cell responses did not even exist (Walker and Slifka,
2010).
For vaccines against single bacterial toxins (e.g., tetanus toxin) or
invariant viruses (e.g., yellow fever virus), analysis of serum
neutralizing antibody titers provides clear and deﬁnitive information
on vaccine efﬁcacy and protection. For instance, a tetanus toxin-
speciﬁc neutralizing titer of≥0.01 IU/mL (Goulon et al., 1972;Wolters
and Dehmel, 1942) or a yellow fever virus-speciﬁc log neutralizing
index (LNI) of ≥0.7 (Mason et al., 1973) is indicative of protective
immunity (Table 1) (Amanna et al., 2008). Immunological analysis is
facilitated by the use of standardized techniques such as neutralizing
assays or enzyme-linked immunosorbent assays (ELISA) and formany
vaccines, there are international serum standards that can be utilized
to validate in-house analysis of serological immunity. For viruses such
as HIV with a high mutation rate and a complex lifecycle, it has been
difﬁcult to develop a single serological assay that can be used for
determining vaccine efﬁcacy — and it is even more problematic to
determine an antibody titer/humoral response that might be
considered protective. There are a number of ways in which virus-
speciﬁc antibodies can interfere with viral infection/replication/
transmission (Burton, 2002; McElrath and Haynes, 2010). For this
reason, there are N10 different assays for measuring HIV-speciﬁc
antibody responses that vary in terms of complexity and the ability to
be standardized and validated (McElrath and Haynes, 2010; Table S1).
This is further complicated by questions regarding which strains of
HIV or pseudovirus are most appropriate to use for determining
antibody responses, etc. Development and distribution of an appro-
priate broadly neutralizing HIV-speciﬁc international serum standard
may also facilitate the standardization of serological tests for
upcoming HIV vaccine candidates.
Analysis of virus-speciﬁc CD4+ and CD8+ T cell responses and
their contribution to vaccine-mediated immunity is more complex
than the analysis of antiviral antibody responses. Because humans
express different haplotypes, different MHC-restricted peptide epi-
topes or whole proteins/virus lysates must be used to evaluate virus-
speciﬁc T cell responses. Are some T cell epitopes more protective
than others? Should a single peptide-speciﬁc response bemeasured as
an immunological endpoint or should multiple peptide epitopes be
measured and the magnitude of the total virus-speciﬁc T cell response
be determined? The breadth of the vaccine-mediated CD8+ T cell
response to HIV may be an important consideration; human vaccine
recipients in the failed Step trial mounted a median response to only
1–2 epitopes from Gag, Pol, and Nef whereas rhesus macaques given
the same vaccine elicited T cell responses to an average of 12 epitopes
and were protected against viral challenge (McElrath and Haynes,
2010; Wilson et al., 2009). One of the complications involved with
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trials, is that different groups often use different approaches and
different controls when quantitating antiviral T cell memory.
However, the state of the art is constantly improving and HIV
research is leading the way. A number of HIV-speciﬁc T cell assays are
in use and two assays, IFNγ ELISPOT and intracellular cytokine
staining by ﬂow cytometry, are among the ﬁrst to be validated
(McElrath and Haynes, 2010). Having standardized/validated techni-
ques is the ﬁrst step necessary to provide unbiased comparisons
between different studies or by different research organizations and
this will likely expedite future vaccine evaluation.
For varicella zoster virus (VZV), an antibody titer of ≥5 gpELISA
units is considered protective (Li et al., 2002), but this serological
endpoint may not be reﬂective of the underlying vaccine-mediated T
cell response, especially at later time points following vaccination
(Amanna et al., 2008). Indeed, this may be an example in which
antibody is a surrogate or a co-correlate of immunity with the relative
contributions by antiviral T cells being difﬁcult to quantify in isolation.
The major immunodominant peptide epitopes of VZV have not been
mapped, so cellular immunity against this virus has been measured
primarily by proliferation assays and skin tests in addition to ELISPOT
assays (Gershon et al., 2008). It is postulated that vaccines that induce
CD8+ T cells with a multifunctional phenotype capable of producing
IFNγ, TNFα, and IL-2 (among others) will be among the best vaccine
candidates. However, development of a relatively high frequency of
vaccine-induced multifunctional HIV-speciﬁc CD8+ T cells during the
Step trial has been disappointing because there appeared to be no
difference in pre-existing T cell memory among patients who became
HIV-infected and their vaccinated controls (McElrath and Haynes,
2010). Many new vaccines against chronic viral pathogens are in
various stages of development and the use of standardized T cell
assays (if feasible) will be important in determining the cellular
correlates of antiviral immunity.
Conclusions
Vaccine-mediated immunity is often multifactorial and the best
protection is likely to be elicited by the combination of strong humoral
and cell-mediated immune responses. Pre-existing virus-speciﬁc
antibody represents the ﬁrst line of defense against infection.
However, if a viral pathogen is able to overcome vaccine-induced
antibody responses and a productive infection occurs, then memory T
cells and memory B cells are mobilized to initiate an anamnestic
program of rapid proliferation and differentiation into effector cells.
Protective immunity provided by the most successful vaccines will
likely be a combination of residual persisting antibody, production of
increased local and systemic levels of antibody bymemory B cells, and
active immunosurveillance for infected cells by rapidly proliferating
virus-speciﬁc T cells. Deﬁning the immunological correlates of
immunity has been relatively straightforward for invariant viral
pathogens in which antibody plays a predominant role in protection.
This has been accomplished through ﬁeld trials (e.g., smallpox),
epidemiological studies (e.g., measles), or animal models (e.g., yellow
fever). For more complex pathogens with complicated lifecycles or
rapid mutation rates, the immunological correlates of protection may
not be known and are likely to include a combination of vaccine-
induced cellular and humoral immune responses. The challenge to
virologists, immunologists, and vaccinologists will be to determine
how to incorporate different levels of cellular and humoral immunity
into a working model or algorithm of inter-related co-correlates that
can be used reliably as a quantitativemeasure of protective immunity.
Antiviral T cell and B cell responses do not act in isolation and
although either arm of the vaccine-induced immune response may
play a predominant role in protective immunity to a particular virus,
they clearly function best together to efﬁciently protect against
disease.Acknowledgments
This work was funded by the National Institute of Allergy and
Infectious Diseases, National Institutes of Health grants, R43 AI079898
(to I.J.A. and M.K.S.), UO1 AI082196 (to M.K.S.), and U54 AI081680 (to
M.K.S.), and ONPRC grant RR00163 (to M.K.S.). Oregon Health and
Science University (OHSU), I.J.A., andM.K.S. have a ﬁnancial interest in
Najít Technologies, Inc., a company that may have a commercial
interest in the results of this research and technology. These potential
conﬂicts of interest have been reviewed and managed by OHSU and
the Integrity Program Oversight Council.
References
Ahuja, A., Anderson, S.M., Khalil, A., Shlomchik, M.J., 2008. Maintenance of the plasma
cell pool is independent of memory B cells. Proc. Natl Acad. Sci. USA 105 (12),
4802–4807.
Amanna, I., Slifka, M.K., 2005. Public fear of vaccination: separating fact from ﬁction.
Viral Immunol. 18 (2), 307–315.
Amanna, I.J., Slifka, M.K., 2009. Wanted, dead or alive: new viral vaccines. Antiviral Res.
84 (2), 119–130.
Amanna, I.J., Slifka, M.K., 2010. Mechanisms that determine plasma cell lifespan and the
duration of humoral immunity. Immunol. Rev. 236, 125–138.
Amanna, I.J., Carlson, N.E., Slifka, M.K., 2007. Duration of humoral immunity to common
viral and vaccine antigens. N. Engl. J. Med. 357 (19), 1903–1915.
Amanna, I.J., Messaoudi, I., Slifka, M.K., 2008. Protective immunity following
vaccination: how is it deﬁned? Hum. Vaccin. 4 (4).
Appay, V., Zaunders, J.J., Papagno, L., Sutton, J., Jaramillo, A., Waters, A., Easterbrook, P.,
Grey, P., Smith, D., McMichael, A.J., Cooper, D.A., Rowland-Jones, S.L., Kelleher,
A.D., 2002. Characterization of CD4(+) CTLs ex vivo. J. Immunol. 168 (11),
5954–5958.
Arnold, P.Y., Davidian, D.K., Mannie, M.D., 1997. Antigen presentation by T cells: T cell
receptor ligation promotes antigen acquisition from professional antigen-present-
ing cells. Eur. J. Immunol. 27 (12), 3198–3205.
Arvin, A.M., Sharp, M., Smith, S., Koropchak, C.M., Diaz, P.S., Kinchington, P., Ruyechan,
W., Hay, J., 1991. Equivalent recognition of a varicella-zoster virus immediate early
protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or
CD8+ phenotype. J. Immunol. 146 (1), 257–264.
Aspinall, R., Del Giudice, G., Effros, R.B., Grubeck-Loebenstein, B., Sambhara, S., 2007.
Challenges for vaccination in the elderly. Immunol. Ageing 4, 9.
Beadling, C., Slifka, M.K., 2006. Quantifying viable virus-speciﬁc T cells without a priori
knowledge of ﬁne epitope speciﬁcity. Nat. Med. 12 (10), 1208–1212.
Belnoue, E., Pihlgren, M., McGaha, T.L., Tougne, C., Rochat, A.F., Bossen, C., Schneider, P.,
Huard, B., Lambert, P.H., Siegrist, C.A., 2008. APRIL is critical for plasmablast survival
in the bone marrow and poorly expressed by early-life bone marrow stromal cells.
Blood 111 (5), 2755–2764.
Benner, R., Hijmans, W., Haaijman, J.J., 1981. The bone marrow: the major source of
serum immunoglobulins, but still a neglected site of antibody formation. Clin. Exp.
Immunol. 46 (1), 1–8.
Benson, M.J., Dillon, S.R., Castigli, E., Geha, R.S., Xu, S., Lam, K.P., Noelle, R.J., 2008.
Cutting edge: the dependence of plasma cells and independence of memory B cells
on BAFF and APRIL. J. Immunol. 180 (6), 3655–3659.
Bernasconi, N.L., Traggiai, E., Lanzavecchia, A., 2002. Maintenance of serological
memory by polyclonal activation of human memory B cells. Science 298 (5601),
2199–2202.
Blanco, J.C., Boukhvalova, M.S., Shirey, K.A., Prince, G.A., Vogel, S.N., 2010. New
insights for development of a safe and protective RSV vaccine. Hum. Vaccin. 6 (6),
482–492.
Bourgault, I., Gomez, A., Gomard, E., Picard, F., Levy, J.P., 1989. A virus-speciﬁc CD4+
cell-mediated cytolytic activity revealed by CD8+ cell elimination regularly
develops in uncloned human antiviral cell lines. J. Immunol. 142 (1), 252–256.
Brown, D.M., Kamperschroer, C., Dilzer, A.M., Roberts, D.M., Swain, S.L., 2009. IL-2 and
antigen dose differentially regulate perforin- and FasL-mediated cytolytic activity
in antigen speciﬁc CD4+ T cells. Cell. Immunol. 257 (1–2), 69–79.
Burton, D.R., 2002. Opinion: antibodies, viruses and vaccines. Nat. Rev. Immunol. 2 (9),
706–713.
Cambridge, G., Leandro, M.J., Edwards, J.C., Ehrenstein, M.R., Salden, M., Bodman-Smith,
M., Webster, A.D., 2003. Serologic changes following B lymphocyte depletion
therapy for rheumatoid arthritis. Arthritis Rheum. 48 (8), 2146–2154.
Casadevall, A., 1999. Passive antibody therapies: progress and continuing challenges.
Clin. Immunol. 93 (1), 5–15.
Cassese, G., Arce, S., Hauser, A.E., Lehnert, K., Moewes, B., Mostarac, M., Muehlinghaus,
G., Szyska, M., Radbruch, A., Manz, R.A., 2003. Plasma cell survival is mediated by
synergistic effects of cytokines and adhesion-dependent signals. J. Immunol. 171
(4), 1684–1690.
CDC, 1998. Advances in global measles control and elimination: summary of the 1997
international meeting. MMWR Recomm. Rep. 47 (RR-11), 1–23.
Chen, R.T., Markowitz, L.E., Albrecht, P., Stewart, J.A., Mofenson, L.M., Preblud, S.R.,
Orenstein, W.A., 1990. Measles antibody: reevaluation of protective titers. J. Infect.
Dis. 162 (5), 1036–1042.
Conrad, R.E., Ingraham, J.S., 1974. Rate of hemolytic antibody production by single cells
in vivo in rabbits. J. Immunol. 112 (1), 17–25.
213I.J. Amanna, M.K. Slifka / Virology 411 (2011) 206–215Crotty, S., Felgner, P., Davies, H., Glidewell, J., Villarreal, L., Ahmed, R., 2003a. Cutting
edge: long-term B cell memory in humans after smallpox vaccination. J. Immunol.
171 (10), 4969–4973.
Crotty, S., Kersh, E.N., Cannons, J., Schwartzberg, P.L., Ahmed, R., 2003b. SAP is required
for generating long-term humoral immunity. Nature 421 (6920), 282–287.
Crotty, S., Aubert, R.D., Glidewell, J., Ahmed, R., 2004. Tracking human antigen-speciﬁc
memory B cells: a sensitive and generalized ELISPOT system. J. Immunol. Meth. 286
(1–2), 111–122.
Cui, W., Kaech, S.M., 2010. Generation of effector CD8+ T cells and their conversion to
memory T cells. Immunol. Rev. 236, 151–166.
Darce, J.R., Arendt, B.K., Wu, X., Jelinek, D.F., 2007. Regulated expression of BAFF-
binding receptors during human B cell differentiation. J. Immunol. 179 (11),
7276–7286.
Dasgupta, A., Hammarlund, E., Slifka, M.K., Fruh, K., 2007. Cowpox virus evades CTL
recognition and inhibits the intracellular transport of MHC class I molecules. J.
Immunol. 178 (3), 1654–1661.
Demkowicz, W.E.J., Littaua, R.A., Wang, J., Ennis, F.A., 1996. Human cytotoxic T-cell
memory: long-lived responses to vaccinia virus. J. Virol. 70, 2627–2631.
DiLillo, D.J., Hamaguchi, Y., Ueda, Y., Yang, K., Uchida, J., Haas, K.M., Kelsoe, G., Tedder,
T.F., 2008. Maintenance of long-lived plasma cells and serological memory despite
mature and memory B cell depletion during CD20 immunotherapy in mice. J.
Immunol. 180 (1), 361–371.
Douglas, R.G., Sadoff, J.C., Samant, V., 2008. The vaccine industry, In: Plotkin, S.A.,
Orenstein, W.A., Ofﬁt, P.A. (Eds.), Vaccines, 5th ed. Saunders/Elsevier, Philadelphia,
PA, pp. 37–44.
Dowdle, W.R., Coleman, M.T., Mostow, S.R., Kaye, H.S., Schoenbaum, S.C., 1973.
Inactivated inﬂuenza vaccines. 2. Laboratory indices of protection. Postgrad. Med. J.
49 (569), 159–163.
Eibl, M.M., 2008. History of immunoglobulin replacement. Immunol. Allergy Clin. North
Am. 28 (4), 737–764 viii.
Elgueta, R., de Vries, V.C., Noelle, R.J., 2010. The immortality of humoral immunity.
Immunol. Rev. 236, 139–150.
Empey, K.M., Peebles Jr., R.S., Kolls, J.K., 2010. Pharmacologic advances in the treatment
and prevention of respiratory syncytial virus. Clin. Infect. Dis. 50 (9), 1258–1267.
Erickson, A.L., Walker, C.M., 1993. Class I major histocompatibility complex-restricted
cytotoxic T cell responses to vaccinia virus in humans. J. Gen. Virol. 74 (Pt 4),
751–754.
FDA, 2010. Complete list of vaccines licensed for immunization and distribution in the
US. http://www.fda.gov/BiologicsBloodVaccines/Vaccies/ApprovedProducts/
UCM093833.
Fenner, F., Henderson, D.A., Arita, I., Jezek, Z., Ladnyi, I.D., 1988. Smallpox and its
eradication. The Pathogenesis, Immunology, and Pathology of Smallpox and
Vaccinia. World Health Organization, Geneva, p. 1469.
Fine, P.E.M., Mulholland, K., 2008. Community immunity, In: Plotkin, S.A., Orenstein, W.
A., Ofﬁt, P.A. (Eds.), Vaccines, 5th ed. Saunders/Elsevier, Philadelphia, PA, pp. 17–36.
Fiore, A.E., Finestone, S.M., Bell, B.P., 2008. Hepatitis A vaccine, In: Plotkin, S.A.,
Orenstein, W.A., Ofﬁt, P.A. (Eds.), Vaccines, 5th ed. Saunders/Elsevier, Philadelphia,
PA, pp. 177–203.
Franco, M.A., Angel, J., Greenberg, H.B., 2006. Immunity and correlates of protection for
rotavirus vaccines. Vaccine 24 (15), 2718–2731.
Gershon, A.A., Takahashi, M., Seward, J.F., 2008. Varicella vaccine. In: Plotkin, S.A.,
Orenstein, W.A., Ofﬁt, P.A. (Eds.), Vaccines. Saunders/Elsevier, Philadelphia, PA,
pp. 915–958.
Goldblatt, D., Miller, E., McCloskey, N., Cartwright, K., 1998. Immunological response to
conjugate vaccines in infants: follow up study. BMJ 316 (7144), 1570–1571.
Gomez, P.L., Robinson, J.M., Rogalewicz, J., 2008. Vaccine manufacturing, In: Plotkin, S.
A., Orenstein, W.A., Ofﬁt, P.A. (Eds.), Vaccines, 5th ed. Saunders/Elsevier,
Philadelphia, PA, pp. 45–58.
Goulon, M., Girard, O., Grosbuis, S., Desormeau, J.P., Capponi, M.F., 1972. Antitetanus
antibodies. Assay before anatoxinotherapy in 64 tetanus patients. Nouv. Presse
Méd. 1 (45), 3049–3050.
Green, S., Kurane, I., Pincus, S., Paoletti, E., Ennis, F.A., 1997. Recognition of dengue virus
NS1–NS2a proteins by human CD4+ cytotoxic T lymphocyte clones. Virology 234
(2), 383–386.
Gyulai, Z., Endresz, V., Burian, K., Pincus, S., Toldy, J., Cox, W.I., Meric, C., Plotkin, S.,
Gonczol, E., Berencsi, K., 2000. Cytotoxic T lymphocyte (CTL) responses to human
cytomegalovirus pp 65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals:
reevaluation of prevalence of IE1-speciﬁc CTLs. J. Infect. Dis. 181 (5), 1537–1546.
Hall-Baker, P.A., Enrique Nieves, J., Jajosky, R.A., Adams, D.A., Sharp, P., Anderson, W.J.,
Aponte, J.J., Aranas, A.E., Katz, S.B., Mayes, M., Wodajo, M.S., Onweh, D.H., Baillie, J.,
Park, M., 2010. Summary of notiﬁable diseases — United States, 2008. MMWR
Morb. Mortal. Wkly Rep. 57, 1–93.
Hansen, S.G., Vieville, C., Whizin, N., Coyne-Johnson, L., Siess, D.C., Drummond, D.D.,
Legasse, A.W., Axthelm, M.K., Oswald, K., Trubey, C.M., Piatak Jr., M., Lifson, J.D.,
Nelson, J.A., Jarvis, M.A., Picker, L.J., 2009. Effector memory T cell responses are
associated with protection of rhesus monkeys from mucosal simian immunode-
ﬁciency virus challenge. Nat. Med. 15 (3), 293–299.
Hargreaves, D.C., Hyman, P.L., Lu, T.T., Ngo, V.N., Bidgol, A., Suzuki, G., Zou, Y.R., Littman,
D.R., Cyster, J.G., 2001. A coordinated change in chemokine responsiveness guides
plasma cell movements. J. Exp. Med. 194 (1), 45–56.
Hauser, A.E., Debes, G.F., Arce, S., Cassese, G., Hamann, A., Radbruch, A., Manz, R.A., 2002.
Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on
plasma blasts during the time course of a memory immune response. J. Immunol.
169 (3), 1277–1282.
Hayden, G. F. (1979). Measles vaccine failure. A survey of causes and means of
prevention. Clin Pediatr (Phila) 18(3), 155–6, 161–3, 167.Hegde, N.R., Johnson, D.C., 2003. Human cytomegalovirus US2 causes similar effects on
both major histocompatibility complex class I and II proteins in epithelial and glial
cells. J. Virol. 77 (17), 9287–9294.
Helmreich, E., Kern, M., Eisen, H.N., 1961. The secretion of antibody by isolated lymph
node cells. J. Biol. Chem. 236, 464–473.
Helmreich, E., Kern, M., Eisen, H.N., 1962. Observations on the mechanism of secretion
of g-globulins by isolated lymph node cells. J. Biol. Chem. 237 (6), 1925–1931.
Hikono, H., Kohlmeier, J.E., Takamura, S., Wittmer, S.T., Roberts, A.D., Woodland, D.L.,
2007. Activation phenotype, rather than central- or effector-memory phenotype,
predicts the recall efﬁcacy of memory CD8+ T cells. J. Exp. Med. 204 (7),
1625–1636.
Holmgren, J., Czerkinsky, C., 2005. Mucosal immunity and vaccines. Nat. Med. 11 (4
Suppl), S45–S53.
Hombach, J., Solomon, T., Kurane, I., Jacobson, J., Wood, D., 2005. Report on a WHO
consultation on immunological endpoints for evaluation of new Japanese
encephalitis vaccines, WHO, Geneva, 2–3 September, 2004. Vaccine 23 (45),
5205–5211.
Huang, J.F., Yang, Y., Sepulveda, H., Shi, W., Hwang, I., Peterson, P.A., Jackson, M.R.,
Sprent, J., Cai, Z., 1999. TCR-mediated internalization of peptide–MHC complexes
acquired by T cells. Science 286 (5441), 952–954.
Hudrisier, D., Bongrand, P., 2002. Intercellular transfer of antigen-presenting cell
determinants onto T cells: molecular mechanisms and biological signiﬁcance.
FASEB J. 16 (6), 477–486.
Hudrisier, D., Riond, J., Mazarguil, H., Gairin, J.E., Joly, E., 2001. Cutting edge: CTLs rapidly
capture membrane fragments from target cells in a TCR signaling-dependent
manner. J. Immunol. 166 (6), 3645–3649.
Huster, K.M., Busch, V., Schiemann, M., Linkemann, K., Kerksiek, K.M., Wagner, H.,
Busch, D.H., 2004. Selective expression of IL-7 receptor on memory T cells identiﬁes
early CD40L-dependent generation of distinct CD8+ memory T cell subsets. Proc.
Natl Acad. Sci. USA 101 (15), 5610–5615.
Hwang, I., Huang, J.F., Kishimoto, H., Brunmark, A., Peterson, P.A., Jackson, M.R., Surh, C.
D., Cai, Z., Sprent, J., 2000. T cells can use either T cell receptor or CD28 receptors to
absorb and internalize cell surface molecules derived from antigen-presenting
cells. J. Exp. Med. 191 (7), 1137–1148.
Hyland, L., Sangster, M., Sealy, R., Coleclough, C., 1994. Respiratory virus infection of
mice provokes a permanent humoral immune response. J. Virol. 68, 6083–6086.
Jack, A.D., Hall, A.J., Maine, N., Mendy, M., Whittle, H.C., 1999. What level of hepatitis B
antibody is protective? J. Infect. Dis. 179 (2), 489–492.
Jansen, V.A., Stollenwerk, N., Jensen, H.J., Ramsay, M.E., Edmunds, W.J., Rhodes, C.J.,
2003. Measles outbreaks in a populationwith declining vaccine uptake. Science 301
(5634), 804.
Jaye, A., Magnusen, A.F., Sadiq, A.D., Corrah, T., Whittle, H.C., 1998. Ex vivo analysis of
cytotoxic T lymphocytes to measles antigens during infection and after vaccination
in Gambian children. J. Clin. Invest. 102 (11), 1969–1977.
Jellison, E.R., Kim, S.K., Welsh, R.M., 2005. Cutting edge: MHC class II-restricted killing in
vivo during viral infection. J. Immunol. 174 (2), 614–618.
Jenner, E., 1798. An Inquiry into the Causes and Effects of the Variolae Vaccinae.
Sampson Low, London.
Jenner, E., 1800. A Continuation of Facts and Observations Relative to the Variolae
Vaccinae, or Cowpox. Sampson Low, London.
Joly, E., Hudrisier, D., 2003. What is trogocytosis and what is its purpose? Nat. Immunol.
4 (9), 815.
Joshi, N.S., Cui, W., Chandele, A., Lee, H.K., Urso, D.R., Hagman, J., Gapin, L., Kaech, S.M.,
2007. Inﬂammation directs memory precursor and short-lived effector CD8(+) T
cell fates via the graded expression of T-bet transcription factor. Immunity 27 (2),
281–295.
Jung, Y.W., Rutishauser, R.L., Joshi, N.S., Haberman, A.M., Kaech, S.M., 2010. Differential
localization of effector and memory CD8 T cell subsets in lymphoid organs during
acute viral infection. J. Immunol. 185 (9), 5315–5325.
Kaech, S.M., Wherry, E.J., Ahmed, R., 2002. Effector and memory T-cell differentiation:
implications for vaccine development. Nat. Rev. Immunol. 2 (4), 251–262.
Kaech, S.M., Tan, J.T., Wherry, E.J., Konieczny, B.T., Surh, C.D., Ahmed, R., 2003. Selective
expression of the interleukin 7 receptor identiﬁes effector CD8 T cells that give rise
to long-lived memory cells. Nat. Immunol. 4 (12), 1191–1198.
Kallies, A., Nutt, S.L., 2007. Terminal differentiation of lymphocytes depends on Blimp-
1. Curr. Opin. Immunol. 19 (2), 156–162.
Kreil, T.R., Burger, I., Bachmann, M., Fraiss, S., Eibl, M.M., 1997. Antibodies protect mice
against challenge with tick-borne encephalitis virus (TBEV)-infected macrophages.
Clin. Exp. Immunol. 110 (3), 358–361.
Krilov, L.R., Weiner, L.B., Yogev, R., Fergie, J., Katz, B.Z., Henrickson, K.J., Welliver Sr., R.C.,
2009. The 2009 COID recommendations for RSV prophylaxis: issues of efﬁcacy, cost,
and evidence-based medicine. Pediatrics 124 (6), 1682–1684.
Lambert, P.H., Liu, M., Siegrist, C.A., 2005. Can successful vaccines teach us how to
induce efﬁcient protective immune responses? Nat. Med. 11 (4 Suppl), S54–S62.
Lawrence, C.W., Braciale, T.J., 2004. Activation, differentiation, and migration of naive
virus-speciﬁc CD8+ T cells during pulmonary inﬂuenza virus infection. J. Immunol.
173 (2), 1209–1218.
Lee, B.Y., Norman, B.A., Assi, T.M., Chen, S.I., Bailey, R.R., Rajgopal, J., Brown, S.T.,
Wiringa, A.E., Burke, D.S., 2010. Single versus multi-dose vaccine vials: an economic
computational model. Vaccine 28 (32), 5292–5300.
Lefrancois, L., 2006. Development, trafﬁcking, and function of memory T-cell subsets.
Immunol. Rev. 211, 93–103.
Li, S., Chan, I.S., Matthews, H., Heyse, J.F., Chan, C.Y., Kuter, B.J., Kaplan, K.M., Vessey, S.J.,
Sadoff, J.C., 2002. Inverse relationship between six week postvaccination varicella
antibody response to vaccine and likelihood of long term breakthrough infection.
Pediatr. Infect. Dis. J. 21 (4), 337–342.
214 I.J. Amanna, M.K. Slifka / Virology 411 (2011) 206–215Lin, Y.C., Chang, M.H., Ni, Y.H., Hsu, H.Y., Chen, D.S., 2003. Long-term immunogenicity
and efﬁcacy of universal hepatitis B virus vaccination in Taiwan. J. Infect. Dis. 187
(1), 134–138.
Littaua, R.A., Takeda, A., Cruz, J., Ennis, F.A., 1992. Vaccinia virus-speciﬁc human CD4+
cytotoxic T-lymphocyte clones. J. Virol. 66 (4), 2274–2280.
Mack, T.M., Noble Jr., J., Thomas, D.B., 1972. A prospective study of serum antibody and
protection against smallpox. Am. J. Trop. Med. Hyg. 21 (2), 214–218.
Mackay, F., Schneider, P., 2009. Cracking the BAFF code. Nat. Rev. Immunol. 9 (7),
491–502.
Manz, R.A., Thiel, A., Radbruch, A., 1997. Lifetime of plasma cells in the bone marrow.
Nature 388 (10), 133–134.
Martorelli, D., Muraro, E., Merlo, A., Turrini, R., Rosato, A., Dolcetti, R., 2010. Role of
CD4+ cytotoxic T lymphocytes in the control of viral diseases and cancer. Int. Rev.
Immunol. 29 (4), 371–402.
Mason, R.A., Tauraso, N.M., Spertzel, R.O., Ginn, R.K., 1973. Yellow fever vaccine: direct
challenge of monkeys given graded doses of 17D vaccine. Appl. Microbiol. 25 (4),
538–544.
Matter, L., Kogelschatz, K., Germann, D., 1997. Serum levels of rubella virus antibodies
indicating immunity: response to vaccination of subjects with low or undetectable
antibody concentrations. J. Infect. Dis. 175 (4), 749–755.
McElrath, M.J., Haynes, B.F., 2010. Induction of immunity to human immunodeﬁciency
virus type-1 by vaccination. Immunity 33 (4), 542–554.
McVernon, J., Johnson, P.D., Pollard, A.J., Slack, M.P., Moxon, E.R., 2003. Immunologic
memory in Haemophilus inﬂuenzae type b conjugate vaccine failure. Arch. Dis.
Child. 88 (5), 379–383.
Metzger, H., 1992. Transmembrane signaling: the joy of aggregation. J. Immunol. 149
(5), 1477–1487.
Miller, J.J., 1964. An autoradiographic study of plasma cell and lymphocyte survival in
rat popliteal lymph nodes. J. Immunol. 92, 673–681.
Miller, J.D., van der Most, R.G., Akondy, R.S., Glidewell, J.T., Albott, S., Masopust, D.,
Murali-Krishna, K., Mahar, P.L., Edupuganti, S., Lalor, S., Germon, S., Del Rio, C.,
Mulligan, M.J., Staprans, S.I., Altman, J.D., Feinberg, M.B., Ahmed, R., 2008. Human
effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines.
Immunity 28 (5), 710–722.
Mitra-Kaushik, S., Cruz, J., Stern, L.J., Ennis, F.A., Terajima, M., 2007. Human cytotoxic
CD4+ T cells recognize HLA-DR1-restricted epitopes on vaccinia virus proteins
A24R and D1R conserved among poxviruses. J. Immunol. 179 (2), 1303–1312.
Monath, T.P., Cetron, M.S., Teuwen, D.E., 2008. Yellow fever vaccine, In: Plotkin,
S.A., Orenstein, W.A., Ofﬁt, P.A. (Eds.), Vaccines, 5th ed. Saunders/Elsevier,
p. 1725.
Morrison, D., Legg, T.J., Billings, C.W., Forrat, R., Yoksan, S., Lang, J., 2010. A novel
tetravalent dengue vaccine is well tolerated and immunogenic against all 4
serotypes in ﬂavivirus-naive adults. J. Infect. Dis. 201 (3), 370–377.
Munz, C., Bickham, K.L., Subklewe, M., Tsang, M.L., Chahroudi, A., Kurilla, M.G., Zhang,
D., O'Donnell, M., Steinman, R.M., 2000. Human CD4(+) T lymphocytes
consistently respond to the latent Epstein–Barr virus nuclear antigen EBNA1. J.
Exp. Med. 191 (10), 1649–1660.
Murali-Krishna, K., Altman, J.D., Suresh, M., Sourdive, D.J.D., Zajac, A.J., Miller, J.D.,
Slansky, J., Ahmed, R., 1998. Counting antigen-speciﬁc CD8 T cells: a reevaluation of
bystander activation during viral infection. Immunity 8, 177–187.
Nalin, D.R., Kuter, B.J., Brown, L., Patterson, C., Calandra, G.B., Werzberger, A., Shouval,
D., Ellerbeck, E., Block, S.L., Bishop, R., et al., 1993. Worldwide experience with the
CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult
populations: an overview. J. Hepatol. 18 (Suppl 2), S51–S55.
Nanan, R., Heinrich, D., Frosch, M., Kreth, H.W., 2001. Acute and long-term effects of
booster immunisation on frequencies of antigen-speciﬁc memory B-lymphocytes.
Vaccine 20 (3–4), 498–504.
Nardelli-Haeﬂiger, D., Wirthner, D., Schiller, J.T., Lowy, D.R., Hildesheim, A., Ponci, F., De
Grandi, P., 2003. Speciﬁc antibody levels at the cervix during the menstrual cycle of
women vaccinated with human papillomavirus 16 virus-like particles. J. Natl
Cancer Inst. 95 (15), 1128–1137.
Nepom, J.T., Benacerraf, B., Germain, R.N., 1981. Acquisition of syngeneic I-A
determinants by T cells proliferating in response to poly (Glu60Ala30Tyr10). J.
Immunol. 127 (3), 888–892.
Nie, Y., Waite, J., Brewer, F., Sunshine, M.J., Littman, D.R., Zou, Y.R., 2004. The role of
CXCR4 in maintaining peripheral B cell compartments and humoral immunity. J.
Exp. Med. 200 (9), 1145–1156.
O'Connor, B.P., Raman, V.S., Erickson, L.D., Cook, W.J., Weaver, L.K., Ahonen, C., Lin, L.L.,
Mantchev, G.T., Bram, R.J., Noelle, R.J., 2004. BCMA is essential for the survival of
long-lived bone marrow plasma cells. J. Exp. Med. 199 (1), 91–98.
Orenstein, W.A., Markowitz, L., Preblud, S.R., Hinman, A.R., Tomasi, A., Bart, K.J., 1986.
Appropriate age for measles vaccination in the United States. Dev. Biol. Stand. 65,
13–21.
Papon, J.F., Coste, A., Gendron, M.C., Cordonnier, C., Wingerstmann, L., Peynegre, R.,
Escudier, E., 2002. HLA-DR and ICAM-1 expression and modulation in epithelial
cells from nasal polyps. Laryngoscope 112 (11), 2067–2075.
Patel, D.M., Arnold, P.Y., White, G.A., Nardella, J.P., Mannie, M.D., 1999. Class II MHC/
peptide complexes are released from APC and are acquired by T cell responders
during speciﬁc antigen recognition. J. Immunol. 163 (10), 5201–5210.
Penna, A., Fowler, P., Bertoletti, A., Guilhot, S., Moss, B., Margolskee, R.F., Cavalli, A., Valli,
A., Fiaccadori, F., Chisari, F.V., et al., 1992. Hepatitis B virus (HBV)-speciﬁc cytotoxic
T-cell (CTL) response in humans: characterization of HLA class II-restricted CTLs
that recognize endogenously synthesized HBV envelope antigens. J. Virol. 66 (2),
1193–1198.
Pierce, S.K., Liu, W., 2010. The tipping points in the initiation of B cell signalling: how
small changes make big differences. Nat. Rev. Immunol. 10 (11), 767–777.Plotkin, S.A., 2005. Why certain vaccines have been delayed or not developed at all.
Health Aff. (Millwood) 24 (3), 631–634.
Plotkin, S.A., 2008. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis.
47 (3), 401–409.
Plotkin, S.A., 2010. Correlates of protection induced by vaccination. Clin. Vaccine
Immunol. 17 (7), 1055–1065.
Plotkin, S.L., Plotkin, S.A., 2008. A short history of vaccination, In: Plotkin, S.A.,
Orenstein, W.A., Ofﬁt, P.A. (Eds.), Vaccines, 5th ed. Saunders/Elsevier, Philadelphia,
PA, pp. 1–16.
Plotkin, S.A., Vidor, E., 2008. Poliovirus vaccine— inactivated, In: Plotkin, S.A., Orenstein,
W.A., Ofﬁt, P.A. (Eds.), Vaccines, 5th ed. Saunders/Elsevier, Philadelphia, PA, pp.
605–630.
Qi, H., Cannons, J.L., Klauschen, F., Schwartzberg, P.L., Germain, R.N., 2008. SAP-
controlled T-B cell interactions underlie germinal centre formation. Nature 455
(7214), 764–769.
Radbruch, A., Muehlinghaus, G., Luger, E.O., Inamine, A., Smith, K.G., Dorner, T., Hiepe, F.,
2006. Competence and competition: the challenge of becoming a long-lived plasma
cell. Nat. Rev. Immunol. 6 (10), 741–750.
Rees, L.E., Ayoub, O., Haverson, K., Birchall, M.A., Bailey, M., 2003. Differential major
histocompatibility complex class II locus expression on human laryngeal
epithelium. Clin. Exp. Immunol. 134 (3), 497–502.
Rosenits, K., Keppler, S.J., Vucikuja, S., Aichele, P., 2010. T cells acquire cell surface
determinants of APC via in vivo trogocytosis during viral infections. Eur. J. Immunol.
40 (12), 3450–3457.
Rossi, G.A., Sacco, O., Balbi, B., Oddera, S., Mattioni, T., Corte, G., Ravazzoni, C., Allegra, L.,
1990. Human ciliated bronchial epithelial cells: expression of the HLA-DR antigens
and of the HLA-DR alpha gene, modulation of the HLA-DR antigens by gamma-
interferon and antigen-presenting function in the mixed leukocyte reaction. Am. J.
Respir. Cell Mol. Biol. 3 (5), 431–439.
Sallusto, F., Lenig, D., Forster, R., Lipp, M., Lanzavecchia, A., 1999. Two subsets of
memory T lymphocytes with distinct homing potentials and effector functions.
Nature 401 (6754), 708–712.
Sallusto, F., Geginat, J., Lanzavecchia, A., 2004. Central memory and effector memory T
cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22,
745–763.
Sallusto, F., Lanzavecchia, A., Araki, K., Ahmed, R., 2010. From vaccines to memory and
back. Immunity 33 (4), 451–463.
Samb, B., Aaby, P., Whittle, H.C., Seck, A.M., Rahman, S., Bennett, J., Markowitz, L.,
Simondon, F., 1995. Serologic status and measles attack rates among vaccinated
and unvaccinated children in rural Senegal. Pediatr. Infect. Dis. J. 14 (3), 203–209.
Sarkar, J.K., Mitra, A.C., Mukherjee, M.K., 1975. The minimum protective level of
antibodies in smallpox. Bull. World Health Organ. 52 (3), 307–311.
Schiller, J.T., Frazer, I.H., Lowy, D.R., 2008. Human papillomavirus vaccines, In: Plotkin, S.
A., Orenstein, W.A., Ofﬁt, P.A. (Eds.), Vaccines, 5th ed. Saunders/Elsevier,
Philadelphia, PA, pp. 243–258.
Schluns, K.S., Kieper, W.C., Jameson, S.C., Lefrancois, L., 2000. Interleukin-7 mediates the
homeostasis of naive and memory CD8 T cells in vivo. Nat. Immunol. 1 (5),
426–432.
Schmid, D.S., 1988. The human MHC-restricted cellular response to herpes simplex
virus type 1 is mediated by CD4+, CD8− T cells and is restricted to the DR region of
the MHC complex. J. Immunol. 140 (10), 3610–3616.
Schwarz, T.F., Leo, O., 2008. Immune response to human papillomavirus after
prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving
upon nature. Gynecol. Oncol. 110 (3 Suppl 1), S1–S10.
Shapiro-Shelef, M., Lin, K.I., Savitsky, D., Liao, J., Calame, K., 2005. Blimp-1 is required for
maintenance of long-lived plasma cells in the bone marrow. J. Exp. Med. 202 (11),
1471–1476.
Siegrist, C.-A., 2008. Vaccine immunology, In: Plotkin, S.A., Orenstein, W.A., Ofﬁt, P.A.
(Eds.), Vaccines, 5th ed. Saunders/Elsevier, p. 1725.
Skendzel, L.P., 1996. Rubella immunity. Deﬁning the level of protective antibody. Am. J.
Clin. Pathol. 106 (2), 170–174.
Slifka, M.K., Ahmed, R., 1998. Long-lived plasma cells: a mechanism for maintaining
persistent antibody production. Curr. Opin. Immunol. 10 (3), 252–258.
Slifka, M.K., Matloubian, M., Ahmed, R., 1995. Bone marrow is a major site of long-term
antibody production after acute viral infection. J. Virol. 69 (3), 1895–1902.
Slifka, M.K., Antia, R., Whitmire, J.K., Ahmed, R., 1998. Humoral immunity due to long-
lived plasma cells. Immunity 8 (3), 363–372.
Spiekermann, G.M., Finn, P.W., Ward, E.S., Dumont, J., Dickinson, B.L., Blumberg, R.S.,
Lencer, W.I., 2002. Receptor-mediated immunoglobulin G transport across mucosal
barriers in adult life: functional expression of FcRn in the mammalian lung. J. Exp.
Med. 196 (3), 303–310.
Stock, A.T., Jones, C.M., Heath, W.R., Carbone, F.R., 2006. Cutting edge: central
memory T cells do not show accelerated proliferation or tissue inﬁltration in
response to localized herpes simplex virus-1 infection. J. Immunol. 177 (3),
1411–1415.
Strebel, P.M., Papania, M.J., Dayan, G.H., Halsey, N.A., 2008. Measles vaccines. In: Plotkin,
S.A., Orenstein,W.A., Ofﬁt, P.A. (Eds.), Vaccines. Saunders/Elsevier, Philadelphia, PA,
pp. 353–398.
Striz, I., Mio, T., Adachi, Y., Carnevali, S., Romberger, D.J., Rennard, S.I., 2000. Effects of
interferons alpha and gamma on cytokine production and phenotypic pattern of
human bronchial epithelial cells. Int. J. Immunopharmacol. 22 (8), 573–585.
Tizard, I., 1999. Grease, anthraxgate, and kennel cough: a revisionist history of early
veterinary vaccines. Adv. Vet. Med. 41, 7–24.
Tokoyoda, K., Zehentmeier, S., Chang, H.D., Radbruch, A., 2009. Organization and
maintenance of immunological memory by stroma niches. Eur. J. Immunol. 39 (8),
2095–2099.
215I.J. Amanna, M.K. Slifka / Virology 411 (2011) 206–215Tomaru, U., Yamano, Y., Nagai, M., Maric, D., Kaumaya, P.T., Biddison, W., Jacobson, S.,
2003. Detection of virus-speciﬁc T cells and CD8+ T-cell epitopes by acquisition of
peptide–HLA–GFP complexes: analysis of T-cell phenotype and function in chronic
viral infections. Nat. Med. 9 (4), 469–476.
Traggiai, E., Puzone, R., Lanzavecchia, A., 2003. Antigen dependent and independent
mechanisms that sustain serum antibody levels. Vaccine 21 (Suppl 2), S35–S37.
Tsang, J.Y., Chai, J.G., Lechler, R., 2003. Antigen presentation by mouse CD4+ T cells
involving acquired MHC class II:peptide complexes: another mechanism to limit
clonal expansion? Blood 101 (7), 2704–2710.
Tulman, E.R., Delhon, G., Afonso, C.L., Lu, Z., Zsak, L., Sandybaev, N.T., Kerembekova, U.Z.,
Zaitsev, V.L., Kutish, G.F., Rock, D.L., 2006. Genome of horsepox virus. J. Virol. 80
(18), 9244–9258.
Valmori, D., Sabbatini, A., Lanzavecchia, A., Corradin, G., Matricardi, P.M., 1994.
Functional analysis of two tetanus toxin universal T cell epitopes in their
interaction with DR1101 and DR1104 alleles. J. Immunol. 152 (6), 2921–2929.
Wahid, R., Cannon, M.J., Chow, M., 2005. Virus-speciﬁc CD4+ and CD8+ cytotoxic
T-cell responses and long-term T-cell memory in individuals vaccinated against
polio. J. Virol. 79 (10), 5988–5995.
Walker, J.M., Slifka, M.K., 2010. Longevity of T-cell memory following acute viral
infection. Adv. Exp. Med. Biol. 684, 96–107.
Wang, D., Levasseur-Acker, G.M., Jankowski, R., Kanny, G., Moneret-Vautrin, D.A.,
Charron, D., Lockhart, A., Swierczewski, E., 1997. HLA class II antigens and T
lymphocytes in human nasal epithelial cells. Modulation of the HLA class II gene
transcripts by gamma interferon. Clin. Exp. Allergy 27 (3), 306–314.
Weibel, R.E., Buynak, E.B., McLean, A.A., Hilleman, M.R., 1975. Long-term follow-up for
immunity after monovalent or combined live measles, mumps, and rubella virus
vaccines. Pediatrics 56 (3), 380–387.
Weinberg, A., Zhang, J.H., Oxman, M.N., Johnson, G.R., Hayward, A.R., Caulﬁeld, M.J.,
Irwin, M.R., Clair, J., Smith, J.G., Stanley, H., Marchese, R.D., Harbecke, R., Williams,
H.M., Chan, I.S., Arbeit, R.D., Gershon, A.A., Schodel, F., Morrison, V.A., Kauffman,
C.A., Straus, S.E., Schmader, K.E., Davis, L.E., Levin, M.J., 2009. Varicella-zoster
virus-speciﬁc immune responses to herpes zoster in elderly participants in a trial
of a clinically effective zoster vaccine. J. Infect. Dis. 200 (7), 1068–1077.
Wetzel, S.A., McKeithan, T.W., Parker, D.C., 2005. Peptide-speciﬁc intercellular transfer
of MHC class II to CD4+ T cells directly from the immunological synapse upon
cellular dissociation. J. Immunol. 174 (1), 80–89.Wherry, E.J., Teichgraber, V., Becker, T.C., Masopust, D., Kaech, S.M., Antia, R., Von
Andrian, U.H., Ahmed, R., 2003. Lineage relationship and protective immunity of
memory CD8 T cell subsets. Nat. Immunol. 4 (3), 225–234.
White, C.J., Kuter, B.J., Ngai, A., Hildebrand, C.S., Isganitis, K.L., Patterson, C.M., Capra, A.,
Miller, W.J., Krah, D.L., Provost, P.J., et al., 1992. Modiﬁed cases of chickenpox after
varicella vaccination: correlation of protection with antibody response. Pediatr.
Infect. Dis. J. 11 (1), 19–23.
Whitehead, S.S., Blaney, J.E., Durbin, A.P., Murphy, B.R., 2007. Prospects for a dengue
virus vaccine. Nat. Rev. Microbiol. 5 (7), 518–528.
Whitmire, J.K., Eam, B., Whitton, J.L., 2008. Tentative T cells: memory cells are quick to
respond, but slow to divide. PLoS Pathog. 4 (4), e1000041.
Whittle, H.C., Maine, N., Pilkington, J., Mendy, M., Fortuin, M., Bunn, J., Allison, L.,
Howard, C., Hall, A., 1995. Long-term efﬁcacy of continuing hepatitis B vaccination
in infancy in two Gambian villages. Lancet 345 (8957), 1089–1092.
Whitton, J.L., Slifka, M.K., Liu, F., Nussbaum, A.K., Whitmire, J.K., 2004. The regulation
and maturation of antiviral immune responses. Adv. Virus Res. 63, 181–238.
WHO, 2007. Rabies vaccines. WHO position paper. Wkly Epidemiol. Rec. 82 (49–50),
425–435.
Wilson, N.A., Keele, B.F., Reed, J.S., Piaskowski, S.M., MacNair, C.E., Bett, A.J., Liang, X.,
Wang, F., Thoryk, E., Heidecker, G.J., Citron, M.P., Huang, L., Lin, J., Vitelli, S., Ahn,
C.D., Kaizu, M., Maness, N.J., Reynolds, M.R., Friedrich, T.C., Loffredo, J.T., Rakasz,
E.G., Erickson, S., Allison, D.B., Piatak Jr., M., Lifson, J.D., Shiver, J.W., Casimiro, D.R.,
Shaw, G.M., Hahn, B.H., Watkins, D.I., 2009. Vaccine-induced cellular responses
control simian immunodeﬁciency virus replication after heterologous challenge.
J. Virol. 83 (13), 6508–6521.
Wolters, K.L., Dehmel, H., 1942. Abschliessende untersuchungen über die tetanu-
sprophylaxe durch aktive immunisierung. Z. Hyg. Infektionskr. 124, 326–332.
Yoon, H., Kim, T.S., Braciale, T.J., 2010. The cell cycle time of CD8 T cells responding in
vivo is controlled by the type of antigenic stimulus. PLoS ONE 5 (11), e15423.
Young, B.W., Lee, S.S., Lim, W.L., Yeoh, E.K., 2003. The long-term efﬁcacy of plasma-
derived hepatitis B vaccine in babies born to carrier mothers. J. Viral Hepat. 10 (1),
23–30.
Zarling, J.M., Eichberg, J.W., Moran, P.A., McClure, J., Sridhar, P., Hu, S.L., 1987.
Proliferative and cytotoxic T cells to AIDS virus glycoproteins in chimpanzees
immunized with a recombinant vaccinia virus expressing AIDS virus envelope
glycoproteins. J. Immunol. 139 (4), 988–990.
